California-based Exelixis, a specialty manufacturer with two high-priced drug products on the market, announced it is further restricting contract pharmacy access to 340B hospitals in a May 31 letter published on 340B ESP.
Sobi Becomes 34th Drugmaker to Implement Contract Pharmacy Restrictions, Exelixis Tightens Contract Pharmacy Policy
Swedish biopharmaceutical company Sobi announced this week that beginning July 1 it will implement 340B contract pharmacy restrictions, making the [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
